Recombinant Human FGFR4 His-tag Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 11120-FR

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
11120-FR-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

CHO

Accession #

P22455.2

Conjugate

Unconjugated

Applications

Bioactivity

View all FGFR4 Proteins and Enzymes »

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived human FGFR4 protein
Leu22-Asp369, with a C-terminal 6-His tag

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Leu22

Predicted Molecular Mass

39 kDa

SDS-PAGE

60-70 kDa, under reducing conditions.

Activity

Measured by its binding ability in a functional ELISA.
In a Human FGF acidic/FGF1 antibody (Catalog # AF232) coated plate, in the presence of 50.0 ng/mL of Recombinant Human FGF acidic/FGF1 (Catalog # 232-FA), Human FGFR4 His-tag Protein binds with an ED50 of 30.0-180 ng/mL.

Scientific Data Images for Recombinant Human FGFR4 His-tag Protein, CF

Recombinant Human FGFR4 His-tag Protein Bioactivity.

In a Human FGF acidic/FGF1 antibody (AF232) coated plate, in the presence of 50.0 ng/mL of Recombinant Human FGF acidic/FGF1 (232-FA), Recombinant Human FGFR4 His-tag Protein (Catalog # 11120-FR) binds with an ED50 of 30.0-180 ng/mL.

Recombinant Human FGFR4 His-tag Protein SDS-PAGE.

2 μg/lane of Recombinant Human FGFR4 His-tag Protein (Catalog # 11120-FR) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 60-70 kDa.

Formulation, Preparation and Storage

11120-FR
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: FGFR4

Fibroblast growth factor receptor 4 (FGFR4) belongs to a family of type I transmembrane tyrosine kinases which mediate the biological functions of FGFs that are involved in a multitude of physiological and pathological cellular processes (1). The FGFR family is comprised of 4 structurally conserved members (FGFR1-4) all possessing and extracellular domain (ECD) with three immunoglobulin (Ig)-like domains, an acid-box region containing a run of acidic residues between the IgI and IgII domains, a transmembrane domain and the split tyrosine-kinase domain (1, 2). The ECD of mature human FGFR4 shares 90% amino acid sequence identity with mouse FGFR4. Alternative splicing of the IgIII domain generates multiple forms of FGFR1-3, but FGFR4 does not have a splice variant (3, 4). FGFR4 exhibits distinct and varying binding affinities for different FGF ligands, with FGF1, FGF4, and FGF8 showing the highest affinity (4). FGFRs mediate the FGF signaling cascade which regulate developmental processes including cellular proliferation, differentiation, and migration, morphogenesis, and patterning (5). FGFRs transduce the signals through three dominant pathways including RAS/MAPK, PI3k/AKT, and PLC gamma (6). FGFR4 is expressed at high levels during embryonic development and is required for the maintenance of both lipid and glucose metabolism as well as an established role in cholesterol metabolism (7). Overexpression of the FGFR4 has been reported in several solid tumors including breast cancer, prostate cancer, pancreatic cancer, and renal cell carcinoma (4, 8). Further, FGFR4 expression is significantly upregulated in most liver cancer cases, and enhanced FGF19-FGFR4 signaling is linked to hepatocellular carcinoma progression, metastasis, and poor survival (8). FGFR4 is being explored as a potential therapeutic target for breast cancer and other solid tumors (9).

References

  1. Ornitz, D.M. and Itoh, N. (2015) Wiley Interdiscip Rev Dev, Biol. 4:215.
  2. Zhang, X. et al. (2006) J Biol Chem. 281:15694.
  3. Ferguson, H.R. et al. (2021) Signaling. Cells 10:1201.
  4. Lang, L. and Teng, Y. (2019) Cells. 8:31.
  5. Xie, Y. et al. (2020) Sig Transduct Target Ther 5:181.
  6. Mossahebi-Mohammadi, M. et al. (2020) Front Cell Dev Biol. 18:79.
  7. Huang, X. et al. (2007) Diabetes 56:2501.
  8. Liu, Y. et al. (2020) Front Cell Dev Biol. 8:95.
  9. Levine, K.M. et al. (2020) Pharmacol Ther. 214:107590.

Long Name

Fibroblast Growth Factor Receptor 4

Alternate Names

CD334, FGF R4

Entrez Gene IDs

2264 (Human); 14186 (Mouse)

Gene Symbol

FGFR4

UniProt

P22455.2

Additional FGFR4 Products

Product Documents for Recombinant Human FGFR4 His-tag Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human FGFR4 His-tag Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.